Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.15 USD
-0.06 (-4.96%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.15 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Aclaris Therapeutics, Inc. [ACRS]
Reports for Purchase
Showing records 1 - 20 ( 31 total )
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
ATI-2138 Near-Term Clinical Progress; 2Q24 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Olumiant Milestones and Royalties Sold; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Pipeline Update; 1Q24 Financial Results; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Balance Sheet Strength; 2023 Financial Results; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
ATI-1777 Trial Data Disappoints; Strategic Reset; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Corporate Update Announced; Headcount Reduction; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Patent License Agreement Inked With Sun Pharma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Zunsemetinib Misses Mark in Rheumatoid Arthritis; Lowering PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Data Catalysts Imminent; 3Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
ATI-1777 Phase 2b Atopic Dermatitis Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
ATI-2138 Phase 1 Trial Reports Positive Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Zunsemetinib Clinical Data Approaching; 2Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Clinical Data Timelines Clarified; 1Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
KOL Call Invite: Getting Under the Skin in HS & PsA
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Zunsemetinib Misses Mark in Hidradenitis Suppurativa; Lowering PT to $43
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Hidradenitis Suppurativa Data Next Month; 2022 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
ATI-1777 China License; 3Q22 Financials; Leadership Changes; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aclaris Therapeutics, Inc.
Industry: Medical - Drugs
Clinical Pipeline Continues to Advance; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R